Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab in osteoarthritis of the knee or hip
NCT02683239Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of fasinumab in knee osteoarthritis (OA), osteoarthritis of the hip, sponsored by Regeneron Pharmaceuticals. Started Feb 2016; status: completed.
02
Drugs
fasinumab
03
Conditions
knee osteoarthritis (OA)osteoarthritis of the hip
Beyond the preview
Go deeper on NCT02683239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683239.